Comparison · NCT04370548-012a3bbd
Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14. Trial comparisons, record NCT04370548-012a3bbd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04370548-012a3bbd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.41 | 0.327 | 0.499 | wilson | |
| Risk in group 2 | 0.0339 | 0.00935 | 0.115 | wilson | |
| Risk difference, group 1 minus group 2 | 0.376 | 0.259 | 0.468 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 12.1 | 3.05 | 48 | log | |
| Odds ratio, group 1 over group 2 | 19.8 | 4.62 | 84.8 | log | |
| Number needed to treat, for one more participant with the outcome on Clindamycin Phosphate Vaginal Gel, 2% than on Placebo Vaginal Gel (Universal HEC Placebo Gel) | 2.66 | 2.14 | 3.85 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clindamycin Phosphate Vaginal Gel, 2% | One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization. | 50 | 122 | OG000 |
| Group 2 | Placebo Vaginal Gel (Universal HEC Placebo Gel) | One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization. | 2 | 59 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14
- Description
- Time frame
- Visit 2, Days 7-14 post randomization
- Population
- mITT population
Source ClinicalTrials.gov
Trial
- Title
- DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
- NCT number
- NCT04370548
- Phases
- PHASE3
- Conditions
- Bacterial Vaginosis
- Interventions
- DARE-BV1clindamycin phosphate vaginal gel, 2%
- Lead sponsor
- Daré Bioscience, Inc.
- Results first posted
- 2021-07-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04370548?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04370548-012a3bbd